CSL (ASX:CSL) acquires a gene therapy candidate

Company News

by Rachael Jones

CSL (ASX:CSL) has agreed to acquire from uniQure exclusive global license rights to commercialise an adeno-associated virus gene therapy program, for the treatment of haemophilia B.

The AMT-061 program, currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with haemophilia B.

The agreement with uniQure will see it receive a $US450 million upfront payment from CSL, followed by regulatory and commercial sales milestone payments and royalties.

Shares in CSL (ASX:CSL) are trading 0.4 per cent higher at $293.55.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.